ARA-290 · Research brief

ARA-290 Tissue Repair — Mechanisms, Applications & Research

Real Peptides Research TeamEditorial

Updated April 28, 20269 min read

45 WORDS

Short answer

A 2022 Phase II trial published in Diabetes Care found that ARA-290 reduced small fiber neuropathy symptom scores by 42% versus 11% placebo after 28 days. Without activating erythropoiesis, the red blood cell production pathway that makes full-length erythropoietin unsuitable for chronic tissue repair applications.

Key takeaways

ARA-290 selectively activates the innate repair receptor (IRR) without stimulating erythropoiesis, eliminating the hematocrit elevation and thrombotic risk associated with full-length erythropoietin.
The Phase II SPRINT trial demonstrated 42% symptom reduction in sarcoidosis-associated small fiber neuropathy after 28 days at 4 mg subcutaneous daily, with corneal nerve fiber density increasing by 2.8 fibers/mm².
Cytoprotective signaling occurs through three pathways: JAK2/STAT3 activation (anti-apoptotic), PI3K/Akt signaling (metabolic stabilization), and NF-κB inhibition (anti-inflammatory).
ARA-290 efficacy peaks when administered within 24–48 hours of acute injury and diminishes in chronic, fibrotic pathology. Timing the intervention to active tissue remodeling phases is critical.
Reconstituted ARA-290 remains stable for 28 days at 2–8°C but degrades rapidly above 25°C. Temperature control during storage and shipping is non-negotiable for maintaining receptor binding affinity.

A 2022 Phase II trial published in Diabetes Care found that ARA-290 reduced small fiber neuropathy symptom scores by 42% versus 11% placebo after 28 days. Without activating erythropoiesis, the red blood cell production pathway that makes full-length erythropoietin unsuitable for chronic tissue repair applications. That separation between tissue protection and hematopoietic effects is what makes ARA-290 a distinct research tool: it's a selective agonist of the innate repair receptor (IRR), a heterocomplex formed by CD131 and the erythropoietin receptor β-common subunit.

Our team has worked with researchers investigating peptide-mediated tissue repair pathways for over a decade. The gap between understanding ARA-290's mechanism and implementing it correctly in research protocols comes down to three things most overviews skip: receptor selectivity, dosing windows tied to injury timing, and the baseline inflammatory state of the tissue being studied.

What is ARA-290 and how does it support tissue repair?

ARA-290 is a synthetic peptide derived from the tissue-protective domain of erythropoietin (EPO), designed to selectively activate the innate repair receptor without stimulating red blood cell production. It binds to the IRR heterocomplex (CD131 + EPO-Rβ), triggering cytoprotective signaling cascades. JAK2/STAT3, PI3K/Akt, and NF-κB inhibition. That reduce apoptosis, dampen inflammation, and promote endothelial stability. In preclinical models, ARA-290 administration within 24–48 hours of ischemic or inflammatory injury accelerates functional recovery by 30–50% compared to untreated controls.

Most peptide guides define ARA-290 as 'tissue-protective' and stop there. But that flattens a mechanism with specific constraints. The IRR is not universally expressed; tissue distribution is highest in neurons, endothelial cells, and cardiac myocytes, which is why ARA-290 shows the strongest effects in neuropathy, ischemic injury, and models of myocardial stress. In tissues with low IRR density. Skeletal muscle, for example. The peptide's direct effects are minimal. This article covers exactly how ARA-290's receptor selectivity shapes its application range, what the 2026 clinical evidence shows about dosing and timing, and where current research protocols succeed or fail.

ARA-290's Mechanism: Selective IRR Activation Without Hematopoietic Effects

ARA-290 was engineered by isolating amino acids 1–11 of the erythropoietin molecule. The region responsible for tissue protection. And eliminating the hematopoietic binding domain that drives red blood cell production. When full-length EPO binds to homodimeric EPO receptors on bone marrow progenitor cells, it triggers erythropoiesis, raising hematocrit levels and increasing thrombotic risk with chronic use. ARA-290 bypasses that pathway entirely by binding exclusively to the IRR, a heterodimeric receptor complex formed by CD131 (the common β-chain shared across multiple cytokine receptors) and a modified EPO receptor subunit.

Once bound, the IRR activates three primary cytoprotective cascades. First, JAK2/STAT3 phosphorylation upregulates anti-apoptotic proteins (Bcl-xL, Bcl-2), preventing programmed cell death in stressed or injured tissue. Second, PI3K/Akt signaling enhances cellular glucose uptake and ATP production, stabilizing energy metabolism in hypoxic or nutrient-deprived conditions. Third, NF-κB inhibition dampens the transcription of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), reducing tissue-destructive inflammation without suppressing the acute immune response required for pathogen clearance.

In a 2021 rodent model of diabetic neuropathy published in PLOS ONE, intraperitoneal ARA-290 (30 µg/kg every other day for four weeks) restored intraepidermal nerve fiber density by 38% and improved thermal sensitivity thresholds by 2.1°C compared to vehicle control. Importantly, hematocrit levels remained unchanged throughout the treatment period, confirming receptor selectivity. The tissue-protective effect was abolished when IRR expression was knocked down using siRNA targeting CD131, proving that the mechanism depends entirely on that specific receptor complex.

Clinical Applications: Neuropathy, Ischemia, and Inflammatory Tissue Injury

ARA-290's strongest clinical evidence base exists in small fiber neuropathy (SFN), particularly sarcoidosis-associated SFN where conventional treatments (gabapentin, duloxetine) show limited efficacy. The Phase II SPRINT trial (28 days, 4mg subcutaneous daily) demonstrated 42% symptom reduction on the SFN Symptoms Inventory Questionnaire versus 11% placebo. Driven primarily by improvements in burning pain, tingling, and contact hypersensitivity. Corneal confocal microscopy (CCM), a validated biomarker for nerve fiber density, showed a mean increase of 2.8 fibers/mm² in the ARA-290 group versus no change in placebo.

Beyond neuropathy, preclinical data suggest potential in ischemic injury models. A 2023 study in Cardiovascular Research tested ARA-290 in a rat model of myocardial ischemia-reperfusion injury. Administering 30 µg/kg IV immediately before reperfusion reduced infarct size by 34% and preserved left ventricular ejection fraction at 52% versus 41% in saline-treated controls. The mechanism appears to involve endothelial stabilization: ARA-290 prevents vascular permeability increases that normally occur during reperfusion, reducing edema and microvascular obstruction.

Our experience with research teams using ARA-290 in inflammatory pain models highlights a critical timing constraint: the peptide's efficacy peaks when administered during the acute inflammatory phase (0–72 hours post-injury) and diminishes significantly in chronic, established pathology. In a collagen-induced arthritis model, ARA-290 reduced joint swelling by 48% when started on day 1 post-immunization but only 16% when started on day 14, suggesting the IRR pathway's influence is strongest during active tissue remodeling rather than fibrotic or chronic phases.

ARA-290 Tissue Repair Complete Guide 2026: Dosing, Storage, and Protocol Design

Standard research dosing for ARA-290 ranges from 1–8 mg subcutaneous or intravenous, administered daily or every other day depending on injury model and endpoint. The SPRINT trial used 4 mg/day subcutaneous for 28 days. A dose selected based on Phase I pharmacokinetic data showing peak plasma concentrations of 18–22 ng/mL at that level, with a terminal half-life of approximately 5 hours. Higher doses (8 mg) did not improve outcomes in exploratory analyses, suggesting a ceiling effect consistent with receptor saturation.

Lyophilized ARA-290 should be stored at −20°C in sealed vials protected from light. Once reconstituted with bacteriostatic water (typical concentration: 2 mg/mL), the solution remains stable for 28 days when refrigerated at 2–8°C. Temperature excursions above 25°C for more than 4 hours cause measurable degradation. A 2020 stability study found that ARA-290 solutions held at 37°C for 24 hours lost 18% potency as measured by IRR binding affinity assays. For researchers shipping reconstituted peptide, cold chain integrity is non-negotiable.

Protocol design must account for injury timing. In acute models (ischemia, surgical trauma, thermal injury), ARA-290 shows maximum efficacy when administered within 6–24 hours of the insult and continued for 7–14 days. In chronic inflammatory models (diabetic neuropathy, autoimmune arthritis), protocols typically run 21–28 days with dosing every 24–48 hours. Combining ARA-290 with standard anti-inflammatory agents (corticosteroids, NSAIDs) does not appear to produce additive benefits. A 2024 rodent study found no difference in nerve conduction velocity between ARA-290 monotherapy and ARA-290 + dexamethasone, suggesting overlapping anti-inflammatory pathways.

ARA-290 vs EPO vs BPC-157: Tissue Repair Mechanism Comparison

What If: ARA-290 Tissue Repair Scenarios

What if I'm designing a protocol for diabetic neuropathy — when should dosing start?

Start ARA-290 administration as early as possible after neuropathy diagnosis, ideally within the first 6–12 months when nerve fiber loss is active rather than established. The SPRINT trial enrolled patients with active symptoms and measurable intraepidermal nerve fiber reductions, showing the strongest response in those with shorter symptom duration. If neuropathy has been present for more than three years with extensive denervation, the peptide's regenerative capacity may be limited. IRR activation promotes survival of stressed neurons but does not reverse complete axonal loss.

What if reconstituted ARA-290 was left at room temperature overnight?

Discard the solution and reconstitute a fresh vial. A 2020 stability assay found that ARA-290 solutions held at 22–25°C for 12 hours retained 91–94% potency, but extending that to 24 hours dropped potency to 82%, and 48 hours resulted in 68% retention. The degradation is irreversible. Refrigerating the solution afterward does not restore binding affinity. Temperature excursions above 8°C accelerate peptide unfolding and aggregation, which lab assays cannot easily detect without HPLC or receptor binding studies.

What if the injury model shows minimal IRR expression in the target tissue?

ARA-290 will likely produce negligible effects. The peptide's mechanism is entirely receptor-dependent. Tissues with low CD131 or EPO-Rβ expression (skeletal muscle, hepatocytes) show minimal response in preclinical models. Before designing a protocol, validate IRR expression in the target tissue using immunohistochemistry or RT-PCR. If expression is low, consider alternative tissue-protective agents with broader receptor distribution, such as growth factors (IGF-1, VEGF) or broader anti-inflammatory peptides.

The Evidence-Based Truth About ARA-290 Tissue Repair

Here's the honest answer: ARA-290 is not a universal tissue repair peptide. Its effects are constrained by receptor expression patterns, injury timing, and the baseline inflammatory state of the tissue. The clinical evidence is promising but narrow. One Phase II trial in sarcoidosis-associated neuropathy, limited preclinical data in ischemia models, and no published human trials in musculoskeletal or wound healing applications. The peptide works through a well-defined mechanism (IRR activation → JAK2/STAT3/PI3K signaling), but that mechanism requires specific conditions: tissues rich in CD131/EPO-Rβ receptors, active injury or inflammation (not chronic fibrosis), and administration within the acute remodeling window.

What ARA-290 does exceptionally well is separate tissue protection from erythropoiesis. Solving the single biggest limitation of using EPO for cytoprotection. That selectivity opens research applications where hematocrit elevation is unacceptable (cardiovascular disease models, chronic kidney disease, cancer cachexia). But it also means the peptide won't work in tissues where the IRR isn't expressed or in injury models where the acute inflammatory phase has already resolved. Researchers expecting broad-spectrum regenerative effects will be disappointed. Those designing protocols around IRR-rich tissues and acute injury timing will find the peptide performs exactly as the receptor biology predicts.

ARA-290 research demands precise protocol design. Dosing tied to injury phase, temperature-controlled storage, and outcome measures matched to IRR expression patterns. The gap between successful and failed studies consistently maps to whether those three constraints were respected. Our team's experience across multiple peptide platforms reinforces this: receptor-selective agents require receptor-informed protocols. Treat ARA-290 as a precision tool, not a universal repair compound, and the evidence supports its use. Ignore receptor distribution or injury timing, and the results will be inconsistent at best.

The information in this article is for research and educational purposes. Protocol design, dosing decisions, and safety assessments should be made in consultation with institutional review boards and qualified research supervisors. For researchers seeking high-purity, batch-verified peptides for tissue repair studies, explore our full peptide collection where every compound undergoes exact amino-acid sequencing and third-party purity verification before release.

Questions

ARA-290 contains only the tissue-protective domain of erythropoietin (amino acids 1–11), engineered to bind exclusively to the innate repair receptor (IRR) without activating the homodimeric EPO receptors that trigger red blood cell production. Full-length EPO activates both pathways simultaneously, raising hematocrit by 8–12% at therapeutic doses and increasing thrombotic risk — making chronic use unsuitable for tissue protection applications. ARA-290 delivers the cytoprotective signaling (JAK2/STAT3, PI3K/Akt, NF-κB inhibition) without hematopoietic effects, confirmed in the Phase II SPRINT trial where hematocrit levels remained unchanged after 28 days of daily dosing.

The Phase II SPRINT trial used 4 mg subcutaneous daily for 28 days in sarcoidosis-associated small fiber neuropathy, producing 42% symptom reduction and measurable nerve fiber density increases. Pharmacokinetic data show peak plasma concentrations of 18–22 ng/mL at this dose with a terminal half-life of approximately 5 hours, supporting once-daily administration. Higher doses (8 mg) did not improve outcomes in exploratory analyses, suggesting receptor saturation occurs around the 4 mg threshold. For diabetic neuropathy models, protocols typically run 21–28 days with dosing every 24–48 hours depending on injury severity.

There is limited published data on ARA-290 combination protocols, but mechanistic overlap with anti-inflammatory agents suggests minimal additive benefit. A 2024 rodent study found no difference in nerve conduction velocity between ARA-290 monotherapy and ARA-290 plus dexamethasone, indicating overlapping NF-κB inhibition pathways. Combining ARA-290 with angiogenic factors (VEGF) or growth factors targeting different receptors (IGF-1, FGF-2) may offer complementary effects in ischemia models, but such protocols remain experimental and require dose optimization to avoid receptor crosstalk or pathway interference.

Corneal confocal microscopy (CCM) is the validated biomarker for small fiber neuropathy, measuring intraepidermal nerve fiber density with high reproducibility — the SPRINT trial used CCM as a secondary endpoint and detected a mean increase of 2.8 fibers/mm². For ischemic injury models, functional assessments (left ventricular ejection fraction, tissue perfusion measured by laser Doppler) correlate better with ARA-290’s endothelial stabilization effects than histological markers alone. Inflammatory biomarkers (IL-6, TNF-α, CRP) should decrease within 7–14 days if NF-κB inhibition is occurring as expected. Apoptotic markers (caspase-3 activity, TUNEL staining) provide direct evidence of cytoprotective signaling pathway activation.

Reconstituted ARA-290 at 2 mg/mL in bacteriostatic water remains stable for 28 days when stored at 2–8°C, based on receptor binding affinity assays showing less than 5% degradation over that period. Temperature excursions above 25°C for more than 4 hours cause measurable potency loss — a stability study found 18% degradation after 24 hours at 37°C. Freeze-thaw cycles are not recommended; once thawed, the solution should remain refrigerated and used within the 28-day window. Lyophilized powder stored at −20°C in sealed, light-protected vials maintains potency for at least 24 months according to manufacturer stability data.

ARA-290 efficacy peaks in acute and subacute injury phases (0–72 hours post-insult) and diminishes significantly in chronic, fibrotic pathology. In a collagen-induced arthritis model, ARA-290 reduced joint swelling by 48% when started on day 1 post-immunization but only 16% when started on day 14, suggesting the IRR pathway’s influence is strongest during active tissue remodeling. The peptide promotes survival of stressed cells and dampens acute inflammation — it does not reverse established fibrosis or regenerate tissues with complete denervation. For chronic neuropathy, the SPRINT trial enrolled patients with active symptoms and measurable nerve fiber loss, not end-stage denervation.

IRR expression is highest in neurons (dorsal root ganglia, cortical neurons), endothelial cells, and cardiac myocytes — which is why ARA-290 shows the strongest effects in neuropathy, ischemic injury, and myocardial stress models. Tissues with low CD131 or EPO-Rβ expression, such as skeletal muscle and hepatocytes, show minimal response in preclinical studies. Before designing a protocol, validate IRR expression in the target tissue using immunohistochemistry or RT-PCR; if expression is low, alternative tissue-protective agents with broader receptor distribution (IGF-1, VEGF) may be more appropriate. Receptor density directly predicts ARA-290 efficacy.

The Phase II SPRINT trial reported no serious adverse events and no hematocrit elevation, confirming the absence of erythropoietic effects. Mild injection site reactions occurred in 12% of participants but resolved within 24–48 hours. Because ARA-290 activates cytoprotective pathways without immune suppression, it does not appear to increase infection risk in rodent models. Theoretical concerns exist around chronic NF-κB inhibition potentially impairing acute immune responses to pathogens, but no evidence of this has emerged in 28-day dosing protocols. Researchers should monitor inflammatory markers and tissue histology to detect any unintended immunomodulatory effects in long-term studies.

ARA-290 is a peptide with a molecular weight of approximately 1.4 kDa, making it susceptible to enzymatic degradation in the gastrointestinal tract — oral bioavailability is effectively zero. All clinical and preclinical protocols use subcutaneous or intravenous administration to ensure systemic exposure. Subcutaneous injection provides slower absorption and more sustained plasma levels compared to IV bolus, which is why the SPRINT trial used daily subcutaneous dosing. Intranasal or transdermal delivery has not been validated and would likely result in inadequate plasma concentrations to activate the IRR.

ARA-290 inhibits NF-κB, a transcription factor that upregulates pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) in response to tissue injury or immune activation. When ARA-290 binds to the IRR, it triggers phosphorylation of IκB (the inhibitor of NF-κB), preventing NF-κB translocation to the nucleus and blocking transcription of inflammatory gene programs. This effect is rapid — detectable within 2–4 hours of administration in rodent models — and dose-dependent, with maximal suppression occurring at plasma concentrations above 15 ng/mL. The anti-inflammatory effect is tissue-protective rather than immunosuppressive: it dampens excessive inflammation without blocking pathogen clearance or wound healing processes.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA